Show simple item record

dc.contributor.authorJereczek-Fossa, BA
dc.contributor.authorMarvaso, G
dc.contributor.authorZaffaroni, M
dc.contributor.authorGugliandolo, SG
dc.contributor.authorZerini, D
dc.contributor.authorCorso, F
dc.contributor.authorGandini, S
dc.contributor.authorAlongi, F
dc.contributor.authorBossi, A
dc.contributor.authorCornford, P
dc.contributor.authorDe Bari, B
dc.contributor.authorFonteyne, V
dc.contributor.authorHoskin, P
dc.contributor.authorPieters, BR
dc.contributor.authorTree, AC
dc.contributor.authorArcangeli, S
dc.contributor.authorFuller, DB
dc.contributor.authorFranzese, C
dc.contributor.authorHannoun-Levi, J-M
dc.contributor.authorJanoray, G
dc.contributor.authorKerkmeijer, L
dc.contributor.authorKwok, Y
dc.contributor.authorLivi, L
dc.contributor.authorLoi, M
dc.contributor.authorMiralbell, R
dc.contributor.authorPasquier, D
dc.contributor.authorPinkawa, M
dc.contributor.authorScher, N
dc.contributor.authorScorsetti, M
dc.contributor.authorShelan, M
dc.contributor.authorToledano, A
dc.contributor.authorvan As, N
dc.contributor.authorVavassori, A
dc.contributor.authorZilli, T
dc.contributor.authorPepa, M
dc.contributor.authorOst, P
dc.contributor.authoron the behalf of the European Society for Radiotherapy, Oncology Advisory Committee on Radiation Oncology Practice (ESTRO ACROP)
dc.date.accessioned2022-06-01T11:57:02Z
dc.date.available2022-06-01T11:57:02Z
dc.identifier.citationCancer treatment reviews, 2021, 98 pp. 102206 - ?en
dc.identifier.issn0305-7372
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5164
dc.identifier.eissn1532-1967en_US
dc.identifier.eissn1532-1967
dc.identifier.doi10.1016/j.ctrv.2021.102206en_US
dc.identifier.doi10.1016/j.ctrv.2021.102206
dc.description.abstract<h4>Background and purpose</h4>Between 30% and 47% of patients treated with definitive radiotherapy (RT) for prostate cancer are at risk of intraprostatic recurrence during follow-up. Re-irradiation with stereotactic body RT (SBRT) is emerging as a feasible and safe therapeutic option. However, no consensus or guidelines exist on this topic. The purpose of this ESTRO ACROP project is to investigate expert opinion on salvage SBRT for intraprostatic relapse after RT.<h4>Materials and methods</h4>A 40-item questionnaire on salvage SBRT was prepared by an internal committee and reviewed by a panel of leading radiation oncologists plus a urologist expert in prostate cancer. Following the procedure of a Delphi consensus, 3 rounds of questionnaires were sent to selected experts on prostate re-irradiation.<h4>Results</h4>Among the 33 contacted experts, 18 (54.5%) agreed to participate. At the end of the final round, participants were able to find consensus on 14 out of 40 questions (35% overall) and major agreement on 13 questions (32.5% overall). Specifically, the consensus was reached regarding some selection criteria (no age limit, ECOG 0-1, satisfactory urinary flow), diagnostic procedures (exclusion of metastatic disease, SBRT target defined on the MRI) and therapeutic approach (no need for concomitant ADT, consideration of the first RT dose, validity of Phoenix criteria for salvage SBRT failure).<h4>Conclusion</h4>While awaiting the results of ongoing studies, our ESTRO ACROP Delphi consensus may serve as a practical guidance for salvage SBRT. Future research should address the existing disagreements on this promising approach.en_US
dc.formatPrint-Electronicen_US
dc.format.extent102206 - ?en_US
dc.languageengen_US
dc.language.isoengen
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden
dc.subjecton the behalf of the European Society for Radiotherapy, Oncology Advisory Committee on Radiation Oncology Practice (ESTRO ACROP)en_US
dc.subjectHumansen_US
dc.subjectProstatic Neoplasmsen_US
dc.subjectNeoplasm Recurrence, Localen_US
dc.subjectSalvage Therapyen_US
dc.subjectRadiosurgeryen_US
dc.subjectConsensusen_US
dc.subjectMaleen_US
dc.subjectPractice Guidelines as Topicen_US
dc.titleSalvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus.en
dc.typeJournal Article
dcterms.dateAccepted2021-04-02
rioxxterms.versionAMen
rioxxterms.versionofrecord10.1016/j.ctrv.2021.102206en
dc.relation.isPartOfCancer treatment reviewsen_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy/Stereotactic and Precision Body Radiotherapy (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume98en_US
pubs.embargo.termsNot knownen_US
icr.researchteamStereotactic and Precision Body Radiotherapy
dc.contributor.icrauthorvan As, Nick
dc.contributor.icrauthorTree, Alison


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record